Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
17 avr. 2023 08h05 HE
|
Panavance Therapeutics Inc.
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ovarian cancer cells include inhibition of glycolysis via modulation of...
Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference
12 avr. 2023 10h05 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
20 mars 2023 10h00 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., March 20, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
05 janv. 2023 10h00 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event
05 déc. 2022 09h05 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022
14 nov. 2022 09h45 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics to Present at BioFuture 2022
02 nov. 2022 10h00 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma
08 août 2022 10h00 HE
|
Panavance Therapeutics Inc.
GP-2250 demonstrated promising antineoplastic effects on malignant mesothelioma cells in vitro, especially in combination with cisplatin/mitomycin C Encouraging data reinforces the basis for further...
Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer
28 juin 2022 10h00 HE
|
Panavance Therapeutics Inc.
BERWYN, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma
09 juin 2022 10h00 HE
|
Panavance Therapeutics Inc.
Combination therapy of GP-2250 and gemcitabine proved to be effective for the treatment of pancreatic neuroendocrine tumors in vitro and in vivo, without the development of secondary resistances Data...